Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Plasma Tech Pionee | Apyx Medical's Renuvion technology offers unique advantages in plastic surgery, with four FDA-approved labels for various applications |
Market Headwinds | Explore how economic uncertainties and a soft capital equipment environment are impacting Apyx's revenue, particularly in U.S. generator sales |
Financial Resilience | Delve into Apyx's financial performance, including a 60.41% gross profit margin and $48.54 million in trailing twelve-month revenue |
Future Prospects | Learn about Apyx's maintained guidance and potential for market expansion as economic conditions improve, with a neutral analyst stance |
Metrics to compare | APYX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPYXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −5.7x | −0.5x | |
PEG Ratio | −0.24 | −0.36 | 0.00 | |
Price/Book | 8.0x | 3.4x | 2.6x | |
Price / LTM Sales | 1.8x | 3.0x | 3.2x | |
Upside (Analyst Target) | 77.8% | 48.3% | 42.7% | |
Fair Value Upside | Unlock | −1.7% | 5.8% | Unlock |